Alkermes Plc

詳細情報 Alkermes Plc 企業名

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Alkermes Plcの企業情報



企業コードALKS

会社名Alkermes Plc

上場日Jul 16, 1991

最高経営責任者「CEO」Mr. Richard F. Pops

従業員数1800

証券種類Ordinary Share

決算期末Jul 16

本社所在地Connaught House

都市DUBLIN

証券取引所NASDAQ Global Select Consolidated

国Ireland

郵便番号D04 C5Y6

電話番号35317728000

ウェブサイトhttps://www.alkermes.com/

企業コードALKS

上場日Jul 16, 1991

最高経営責任者「CEO」Mr. Richard F. Pops

Alkermes Plcの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

205.37K

+0.55%

Mr. Shane M. Cooke

Independent Director

103.74K

+3.84%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

69.74K

-5.42%

Mr. Brian P. Mckeon

Independent Director

43.87K

+16.12%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+24.36%

Dr. Cato T. Laurencin, M.D., Ph.D.

Independent Director

29.10K

+26.46%

Dr. Christopher I. Wright, M.D., Ph.D.

Independent Director

23.01K

+12.23%

Ms. Nancy S. Lurker

Independent Director

10.71K

+131.91%

Dr. Nancy L. Snyderman, M.D.

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

205.37K

+0.55%

Mr. Shane M. Cooke

Independent Director

103.74K

+3.84%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

69.74K

-5.42%

Mr. Brian P. Mckeon

Independent Director

43.87K

+16.12%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+24.36%

収益内訳

通貨: USD更新時刻: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

事業別USD

会社名

収益

比率

VIVITROL

121.66M

31.14%

ARISTADA

101.30M

25.93%

LYBALVI

84.28M

21.57%

Royalty Revenue - VUMERITY

32.02M

8.20%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

30.32M

7.76%

他の

21.09M

5.40%

データなし

事業別

地域別

事業別USD

会社名

収益

比率

VIVITROL

121.66M

31.14%

ARISTADA

101.30M

25.93%

LYBALVI

84.28M

21.57%

Royalty Revenue - VUMERITY

32.02M

8.20%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

30.32M

7.76%

他の

21.09M

5.40%

株主

更新時刻: Sat, Aug 16

株主統計

種類

株主統計

比率

BlackRock Institutional Trust Company, N.A.

14.37%

The Vanguard Group, Inc.

10.98%

T. Rowe Price Associates, Inc.

5.97%

State Street Investment Management (US)

4.97%

Baker Bros. Advisors LP

3.88%

他の

59.83%

株主統計

比率

BlackRock Institutional Trust Company, N.A.

14.37%

The Vanguard Group, Inc.

10.98%

T. Rowe Price Associates, Inc.

5.97%

State Street Investment Management (US)

4.97%

Baker Bros. Advisors LP

3.88%

他の

59.83%

種類

株主統計

比率

Investment Advisor

53.57%

Investment Advisor/Hedge Fund

29.42%

Hedge Fund

14.45%

Research Firm

3.16%

Pension Fund

2.38%

Individual Investor

1.65%

Sovereign Wealth Fund

1.18%

Private Equity

0.61%

Bank and Trust

0.44%

機関投資家保有株



更新時刻: Wed, Oct 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q3

743

174.30M

105.56%

-28.06M

2025Q2

770

179.09M

108.49%

-26.85M

2025Q1

781

180.42M

109.41%

-27.12M

2024Q4

750

175.04M

107.61%

-39.68M

2024Q3

727

186.93M

115.42%

-33.14M

2024Q2

708

187.79M

113.20%

-24.77M

2024Q1

682

184.21M

108.96%

-28.40M

2023Q4

653

184.12M

110.36%

-5.13M

2023Q3

620

171.53M

102.92%

-4.71M

2023Q2

610

167.10M

100.38%

-17.86M

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

BlackRock Institutional Trust Company, N.A.

23.73M

14.37%

-251.67K

-1.05%

Jun 30, 2025

The Vanguard Group, Inc.

18.45M

11.18%

+290.40K

+1.60%

Jun 30, 2025

T. Rowe Price Associates, Inc.

9.86M

5.97%

-1.76M

-15.13%

Jun 30, 2025

State Street Investment Management (US)

8.21M

4.97%

+185.59K

+2.31%

Jun 30, 2025

Baker Bros. Advisors LP

6.41M

3.88%

+1.93M

+42.99%

Jun 30, 2025

Renaissance Technologies LLC

5.81M

3.52%

+71.33K

+1.24%

Jun 30, 2025

RTW Investments L.P.

4.68M

2.84%

-2.20M

-31.99%

Jun 30, 2025

Geode Capital Management, L.L.C.

4.02M

2.44%

+83.86K

+2.13%

Jun 30, 2025

American Century Investment Management, Inc.

3.66M

2.22%

+191.55K

+5.53%

Jun 30, 2025

JP Morgan Asset Management

3.95M

2.39%

-179.85K

-4.36%

Jun 30, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 0.00 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

データなし

株式分割



日付

種類

比率

データなし

日付

種類

比率

データなし

詳細情報 Alkermes Plc 企業名

Alkermes Plcの企業情報

Alkermes Plcの経営陣

収益内訳

株主

機関投資家保有株

株主動向

関連ETF

配当金

株式分割